SolriamfetolClinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

Sponsor:

Axsome Therapeutics, Inc.

Code:

NCT07484217

Conditions

Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Solriamfetol 150 MG

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by Axsome Therapeutics, Inc. on 2026-07-24.